This has led to the FDA approval of the first immunotherapy in breast cancer, anti-PD-L1 (atezolizumab) in combination with chemotherapy (nab-paclitaxel) for metastatic TNBC 127,128. The gene discussed is CD274; the disease is breast carcinoma.